Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$129.46
$128.90
$84.25
$129.65
$8.36B0.893.86 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$72.50
+3.5%
$52.15
$22.28
$73.91
$28.77B1.059.22 million shs6.69 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$290.74
+2.0%
$290.36
$239.25
$385.22
$31.90B0.49262,361 shs339,929 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$35.03
-1.0%
$29.88
$10.70
$35.90
$25.20B1.136.14 million shs4.37 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
0.00%0.00%0.00%0.00%+1.00%
Moderna, Inc. stock logo
MRNA
Moderna
+0.47%+14.80%+48.40%+39.98%+153.82%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-1.73%+3.20%-1.02%-7.61%+17.72%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+1.90%+9.87%+18.01%+27.12%+214.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$129.46
$128.90
$84.25
$129.65
$8.36B0.893.86 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$72.50
+3.5%
$52.15
$22.28
$73.91
$28.77B1.059.22 million shs6.69 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$290.74
+2.0%
$290.36
$239.25
$385.22
$31.90B0.49262,361 shs339,929 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$35.03
-1.0%
$29.88
$10.70
$35.90
$25.20B1.136.14 million shs4.37 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
0.00%0.00%0.00%0.00%+1.00%
Moderna, Inc. stock logo
MRNA
Moderna
+0.47%+14.80%+48.40%+39.98%+153.82%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-1.73%+3.20%-1.02%-7.61%+17.72%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+1.90%+9.87%+18.01%+27.12%+214.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
0.00
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$37.13-48.78% Downside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.93
Moderate Buy$390.0034.14% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$33.59-4.11% Downside

Current Analyst Ratings Breakdown

Latest BPMC, ONC, MRNA, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingMarket Outperform$396.00
6/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetOverweight$69.00 ➝ $77.00
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
6/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$32.00 ➝ $34.00
6/4/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
UpgradeHoldStrong-Buy
6/2/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOutperform$425.00 ➝ $436.00
5/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingNeutral
5/26/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$30.00 ➝ $36.00
5/22/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
DowngradeSell (D)Sell (D-)
5/21/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Reiterated RatingOverweight
(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$562.12M14.87N/AN/A$4.70 per share27.54
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B14.80N/AN/A$22.14 per share3.27
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B5.97$3.92 per share74.19$39.77 per share7.31
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,050.37N/AN/A$7.35 per share4.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4765.0427.53N/A8.94%12.06%6.69%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/10/2026 (Estimated)

Latest BPMC, ONC, MRNA, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2026Q4 2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.2893$0.28+$0.5693$0.28$3.41 million$2.52 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/1/2026Q1 2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/A$0.25N/A$1.95N/A$1.51 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
18.37
18.37

Institutional Ownership

CompanyInstitutional Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
4.21%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.19%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860719.27 million641.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Moderna stock logo

Moderna NASDAQ:MRNA

$72.50 +2.47 (+3.53%)
Closing price 04:00 PM Eastern
Extended Trading
$72.42 -0.08 (-0.10%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$290.74 +5.77 (+2.02%)
Closing price 04:00 PM Eastern
Extended Trading
$290.52 -0.22 (-0.07%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$35.03 -0.36 (-1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$35.07 +0.04 (+0.11%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.